Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that finasteride delivered through dissolving microneedles enhanced skin drug permeation compared to films, suggesting potential for improved androgenetic alopecia treatment with fewer side effects.

This study found that after 12 months of treatment with 5 mg of finasteride, patients with benign prostatic hyperplasia showed reduced prostate volume, DHT and PSA levels, and improved urinary flow rates and symptoms.

This review examines hormonal therapies, including finasteride, dutasteride, spironolactone, and oral contraceptives, for treating hidradenitis suppurativa, summarizing various clinical study outcomes but reporting no new clinical results.

This review discusses the pharmacology of 5-alpha reductase inhibitors, their expanding clinical indications beyond benign prostatic hyperplasia, and notes unresolved claims about their potential role in SARS-CoV-2.

This review outlines the scope of hair restoration in men, covering both surgical and medical approaches, but provides no new clinical results.

This study suggests that hesperidin may regulate pathways in hair follicle cells to help mitigate hair loss, revealing molecular mechanisms of nitric oxide donor-mediated hair follicle protection.

Minoxidil sulfate gel can be used to treat hair loss.

The MHRA announced on 11 May 2026 that it will update the product information for finasteride and dutasteride to include more details on potential psychiatric and sexual side effects, following a review of existing evidence.

This study found that finasteride significantly reduced serum dihydrotestosterone levels, confirming its efficacy as a 5a-reductase inhibitor, while Permixon showed no effect in healthy male volunteers.

This article discusses cultural perspectives on hirsutism and hypertrichosis and reports no new clinical results.

This review found that while finasteride may improve female pattern hair loss and hirsutism in women, more long-term studies are needed to optimize its use and assess potential consequences.

This study observed that patients using Erol(®) Energy shampoo and tonic reported improved symptoms of scalp irritation and rated product tolerance as good to excellent.

This study found that microemulsion and microemulsion-based hydrogels may offer a more effective and sustained topical delivery method for minoxidil compared to conventional solutions for hair loss treatment.

This study highlights the gap between media claims and limited scientific evidence on the impact of alternative therapies for men's health, emphasizing the need for larger-scale trials for informed patient counseling.

This study found that while cyproterone acetate, finasteride, and spironolactone had similar short-term effects in treating idiopathic hirsutism, spironolactone provided more lasting benefits one year after treatment.

This review summarizes preclinical and clinical information on herbal products for hair loss treatment, highlighting their mechanisms, follicular penetration, and potential side effects, suggesting they may offer alternatives to synthetic drugs with fewer side effects.

This report discusses the improved access to care and patient benefits of telemedicine for men with androgenetic alopecia, but it provides no new clinical results.

This study found that the Mark Cuban Cost Plus Drug Company model offers substantial cost savings on men's health medications compared to Medicare and GoodRx, particularly for long-term treatments.

This article discusses the author's experience attending the annual Italian Society for Hair Restoration meeting and does not report any scientific findings.

This study developed a precise and simple HPLC method for estimating tamsulosin and finasteride simultaneously in pharmaceutical forms, demonstrating good precision and potential usefulness for combined dosage analysis.

This article discusses the physiology of hair growth, how to identify excessive hair growth in women, and when to refer them for further medical assessment, but reports no new clinical results.

This study found that the "pink tax" persists in topical minoxidil products, with foams marketed to women costing about 20% more than those for men, despite identical ingredients and an overall price increase since 2017.

This review discusses the causes, clinical features, diagnostic approach, and treatment options for hirsutism in women, but reports no new findings.

This study surveyed individuals seeking estrogen-based gender-affirming hormone therapy, revealing that improving life satisfaction and femininity are top treatment goals, and highlighting the need for trials aligned with community priorities.